Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2 Pt 1
|
pubmed:dateCreated |
1998-3-16
|
pubmed:abstractText |
The mechanisms that underlie reocclusion during thrombolytic therapy have not yet been clarified. The purpose of this study was to investigate the activating effects of tissue-type plasminogen activator and urokinase and the inhibitory effects of acetylsalicylic acid by measuring platelet surface P-selectin as a marker of platelet activation. After addition of urokinase (final concentration 192 U/ml, 1920 U/ml, or 19,200 U/ml) or tissue-type plasminogen activator (final concentration 120 U/ml, 1200 U/ml, or 12,000 U/ml) to platelet-rich plasma from 12 healthy persons, platelet surface P-selectin expression was measured by means of flow cytometry with an anti-CD62 monoclonal antibody. The presence of urokinase and tissue-type plasminogen activator increased platelet surface P-selectin expression in a concentration-dependent manner. In the next step, either 160 mg/day (n = 6) or 660 mg/day (n = 6) acetylsalicylic acid was administered to the 12 healthy persons, and venous blood samples were collected after 7 days of treatment. Platelet surface P-selectin expression was measured with the method used earlier and after addition of tissue-type plasminogen activator or urokinase. Although the effect of acetylsalicylic acid at 160 mg/day on P-selectin expression was minimal, a dose of 660 mg/day suppressed platelet P-selectin expression and inhibited the platelet activating effects of tissue-type plasminogen activator and urokinase in a statistically significant way. Platelets were activated by tissue-type plasminogen activator or urokinase, and this platelet activation was suppressed with administration of acetylsalicylic acid at 660 mg/day.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/P-Selectin,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0002-8703
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
135
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
268-71
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:9489975-Aspirin,
pubmed-meshheading:9489975-Blood Platelets,
pubmed-meshheading:9489975-Flow Cytometry,
pubmed-meshheading:9489975-Humans,
pubmed-meshheading:9489975-P-Selectin,
pubmed-meshheading:9489975-Plasminogen Activators,
pubmed-meshheading:9489975-Platelet Activation,
pubmed-meshheading:9489975-Tissue Plasminogen Activator,
pubmed-meshheading:9489975-Urokinase-Type Plasminogen Activator
|
pubmed:year |
1998
|
pubmed:articleTitle |
Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.
|
pubmed:affiliation |
Second Department of Internal Medicine, Kyorin University School of Medicine, Mitaka-city, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|